Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genmark Diagnostics (GNMK)

Genmark Diagnostics (GNMK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genmark Diagnostics 5964 LA PLACE COURT CARLSBAD CA 92008 USA

P: 760-448-4300

Description:

GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor' XT-8 system is the second generation in GenMark Dx's eSensor' platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.

Key Statistics

Overview:

Market Capitalization, $K 368,758
Shares Outstanding, K 57,439
Annual Sales, $ 70,760 K
Annual Net Income, $ -50,500 K
Last Quarter Sales, $ 18,370 K
Last Quarter Net Income, $ -13,310 K
60-Month Beta 1.27
% of Insider Shareholders 5.24%
% of Institutional Shareholders 90.74%
Float, K 54,429
% Float 94.76%

Growth:

1-Year Return -12.53%
3-Year Return -27.81%
5-Year Return -38.89%
5-Year Revenue Growth 158.25%
5-Year Earnings Growth -10.98%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/05/19
Earnings Per Share ttm -0.85
EPS Growth vs. Prev Qtr -9.52%
EPS Growth vs. Prev Year 23.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

GNMK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -7.91
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -167.54
Return-on-Assets (Before Tax) -52.13
Profit Margin % -71.37
Net Margin % -664.70
Debt/Equity 2.23
Price/Sales 5.21
Price/Cash Flow N/A
Price/Book 24.94
Book Value/Share 0.26
Interest Coverage -15.19
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar